Aura Biosciences Q2 2022 net loss $13.5M; cash $122.1M; NMIBC trial on track

Aura Biosciences, Inc.

2022-Q2 EPS reported -$0.90

Net loss $13.5M for Q2 2022 vs $8.9M in Q2 2021; R&D expense rose to $9.5M from $6.6M.
Cash and equivalents $122.1M; sufficient to fund operations into 2024.
On track to dose first patient in Phase 1 NMIBC trial in Q3 2022; FDA Fast Track granted.
On track to initiate pivotal trial in early-stage choroidal melanoma in Q4 2022.
Plans to file IND for choroidal metastases in Q4 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.